For COVID-19 and vaccination updates, view our information for the community. If you're experiencing symptoms, call your primary care provider.

Decorative dot pattern background image.
Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image.

Alliance A221505

Trial Overview

Official Title

Phase III Randomized Trial of Hypo-fractionated Post Mastectomy Radiation with Breast Reconstruction

Study Purpose

To determine if a shorter course of radiation therapy (3-4 weeks) is as safe and effective as the typical 5 to 6 week treatment course after mastectomy.

Diagnosis

Invasive Cancer of the Breast

Eligibility

Planned radiation and re-construction after mastectomy

No prior radiation therapy

No prior history of breast cancer

No other cancers within 5 years prior to registration on this study

Patients must sign an approved informed consent and authorization permitting release of personal health information.

Intervention

  • Radiation Therapy
  • Group 1: 5-6 weeks of radiation therapy (usual approach)
  • Group 2: 3-4 weeks of hypofractionated radiation therapy
  • Quality of Life Questionnaires

All patients enrolled on this trial will receive radiation after mastectomy.  All patients will also have breast reconstruction.  The reconstruction can be done at the time of the mastectomy before enrollment to the study, or as a separate surgery later.  

The study doctor will continue to watch for side effects and follow your condition for 5 years after the completion of radiation therapy.

For more information, visit ClinicalTrials.gov

Key Participation Requirements
Gender
Female
Age
19 years and older
Phase
Phase III
Methodist Health System Trial Code
A221505
Related Specialties